Development milestone payment.

No definition available.

Name:	pulm_DevelopmentMilestonePayment
Namespace Prefix:	pulm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development milestone payment, threshold period from trial initiation.

+ References

No definition available.

+ Details

Name:	pulm_DevelopmentMilestonePaymentThresholdPeriodFromTrialInitation
Namespace Prefix:	pulm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreement, termination description.

+ References

No definition available.

+ Details

Name:	pulm_LicenseAgreementTerminationDescription
Namespace Prefix:	pulm_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreement termination notice period.

+ References

No definition available.

+ Details

Name:	pulm_LicenseAgreementTerminationNoticePeriod
Namespace Prefix:	pulm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	pulm_MilestonePayments
Namespace Prefix:	pulm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty percentage based on net sales.

+ References

No definition available.

+ Details

Name:	pulm_RoyaltyPercentageBasedOnNetSales
Namespace Prefix:	pulm_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=pulm_DevelopmentAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Agreements - Additional Information (Detail) - USD ($)		12 Months Ended
	Jun. 09, 2017	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017
Other Commitments [Line Items]
Milestones payments			$ 0
Research and development expense			$ 12,966,000	$ 10,243,000
License Agreement [Member]
Other Commitments [Line Items]
License fee	$ 1,000,000,000
License agreement termination description			the License Agreement may be terminated (i) by the Company for any reason upon 120 days’ advance notice to RespiVert; (ii) by RespiVert upon receipt of notice from the Company of either voluntary or involuntary insolvency proceedings of the Company; and (iii) by either party for a material breach which remains uncured following the applicable cure period.
License agreement termination notice period			120 days
Research and development expense				$ 1,000,000,000
License Agreement [Member] \| Maximum [Member]
Other Commitments [Line Items]
Range of royalties based on sales, percentage	10.00%
License Agreement [Member] \| Minimum [Member]
Other Commitments [Line Items]
Range of royalties based on sales, percentage	6.00%
License Agreement [Member] \| Scenario Forecast [Member]
Other Commitments [Line Items]
Development milestone payment		$ 1,000,000,000
Development milestone payment period		10 days
Development and Commercial Milestones [Member] \| License Agreement [Member] \| Maximum [Member]
Other Commitments [Line Items]
Milestones payments	$ 1,000,000,000
Development and Commercial Milestones [Member] \| License Agreement [Member] \| Minimum [Member]
Other Commitments [Line Items]
Milestones payments	$ 80,000,000,000